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Objectives: To evaluate in a prospective, randomized clinical trial (RCT), symptom response among obese
knee osteoarthritis (OA) patients following a feasible, intensive weight-loss program for 16 weeks.
Methods: Eligible patients were obese [body mass index (BMI)> 30 kg/m2]; >50 years old, with primary
knee OA.
Participants were randomized to either a very-low-energy diet (VLED) or a low-energy diet (LED)
(415 kcal/day and 810 kcal/day, respectively), using commercially available formula foods e only for the
ﬁrst 8 weeks, managed by dieticians. The 8 weeks were followed by an additional 8-week period of
a hypo-energetic diet consisting of normal food plus meal replacements (1200 kcal/day). The primary
endpoint was the number of patients responding according to the Outcome Measures in Rheumatology
Clinical Trials and Osteoarthritis Research Society International (OMERACTeOARSI) responder criterion.
The statistical analysis was based on a non-responder intention-to-treat (ITT) population (baseline
observation carried forward).
Results: One hundred and ninety two patients (155 (80.7%) females) with a mean age 62.5 years
[standard deviation (SD) 6.4; range 50e78 years]; average BMI 37.3 (SD 4.8) were included. At 16 weeks,
similar proportions of the VLED and LED groups, 59 (61.5%), and 63 (65.6%) patients, respectively, met the
OMERACTeOARSI responder criteria, with no statistical signiﬁcant difference between the groups
(P¼ 0.55). Combining the groups the pooled estimate was 64% meeting the responder criteria [95%
conﬁdence interval (CI) 57%, 70%]. There was an overall reduction in pain, corresponding to an average
pain reduction on the visual analogue scale (VAS) of 11.1 (95%CI 13.6, 8.5) in the combined groups. At
week 16 weight loss in the combined groups was 12.8 kg (95%CI: 11.84e13.66; P< 0.001). 71% lost 10%
body weight in both diet groups, with a pooled estimate of 74% (95%CI: 68e80%).
Conclusion: No clinically signiﬁcant differences were found between the 415 kcal/day and 810 kcal/day
diets.
A 16-week formula-diet weight-loss program resulted in a fast and effective weight loss with very few
adverse events resulting in a highly signiﬁcant improvement in symptoms in overweight patients with
knee OA.
ClinicalTrials.gov Identiﬁer: NCT00655941.
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. Bliddal).
s Research Society International. PIntroduction
In osteoarthritis (OA) the knee is the most commonly affected
weight-bearing joint with the cardinal symptoms of pain and loss
of function1,2. Decreased mobility leading to muscle atrophy, an
accelerated decline in physical function, and the inability to engage
in activities of daily living such as walking and climbing stairs are
clinical consequences that often lead to loss of independence andublished by Elsevier Ltd. All rights reserved.
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functional problems in more than 10% of the population older than
54 years, and one in four will be severely functionally disabled4.
Risks of incident OA are obesity, generalized OA, knee malalign-
ment and synovitis5.
The lifetime risk of symptomatic knee OA rises with increasing
Body Mass Index (BMI), with a risk of 2 in 3 among those who are
obese6. The incidence of obesity is increasing, and at the same time
the age proﬁle of the population changes towards older age. This
leads to an expected accumulation of patients having concomitant
OA and obesity7,8. OA is thus one of many diseases in which obesity
must be taken into serious account for future healthcare planning9.
There is evidence that by treating the obesity of patients with co-
occurring OA effectively, the functional status is dramatically
improved, with the short-term result equal to that of a joint
replacement9,10. Based on meta-regression analyses, signiﬁcant
weight loss is an effective symptom reducing therapy in knee OA
patients with concomitant obesity11. As a consequence the OARSI
guidelines recommend that patients with knee OA who are over-
weight should be encouraged to lose weight and maintain their
weight at a lower level12.
As a more intensive weight-loss strategy could result in a more
pronounced clinical effect11 the aim of our study was to compare
whether there would be an advantage in using a Very-Low Energy
Diet (VLED, 415 kcal/day), compared to a low-energy diet (LED,
810 kcal/day) on short-term followup in obese patients with knee
OA. The primary objective was to compare the number of
responders among obese OA patients following a feasible, intensive
16 week weight-loss program, according to the Outcome Measures
in Rheumatology Clinical Trials and Osteoarthritis Research Society
International (OMERACTeOARSI) response criteria13,14.
Patients and methods
Study design
This was a prospective, pragmatic randomized clinical trial
(RCT), with blinded outcome assessors: the CAROT-study (Inﬂuence
of weight loss or exercise on cartilage in obese knee osteoarthritis
patients: a RCT, ClinicalTrials.gov identiﬁer: NCT00655941.). The
present report is based on the ﬁrst trial phase of 16weeks, initiating
weight loss using dietary intervention with a LED, evaluating
outcomes at two pre-speciﬁed time-points. The primary endpoint
was the number of patients responding according to the OMER-
ACTeOARSI responder criterion after 16 weeks of treatment13.
Patient selection
Patients were recruited from November 2007 until August 2008
from the outpatients' clinic at the Department of Rheumatology at
Frederiksberg Hospital, Frederiksberg. General practitioners in the
local area were informed about the possibility to assign patients to
the project. The study was advertised in newspapers and on the
website of The Parker Institute. All potential trial participants were
contacted by telephone and asked a series of standard questions
according to the pre-speciﬁed eligibility criteria. The study was
approved by the local ethical committee of The Capital Region of
Denmark [H-B-2007-088] and the RCT was done according to the
Helsinki criteria. The studywas designed as a pragmatic triale a RCT
whosepurpose is to informdecisions about effectivenesswhenused
in normal practice; i.e., excluding as few patients as possible
from participation and being directly relevant to healthcare
practitioners15. Eligibility criteria were obesity (BMI> 30 kg/m2);
more than 50 years of age, primary knee OA diagnosed according to
the American College of Rheumatology criteria16, with clinical signsand symptoms as well as radiologically or arthroscopically veriﬁed
OA in one or both knees. Exclusion criteria were: previous or plan-
ned total knee replacement (TKA) in the target knee; surgical
procedures as e.g., arthroscopy or injections into a knee within 3
months prior to enrolment; pharmacological therapy with weight
reducing drugs; lack of motivation to lose weight; inability to speak
Danish ﬂuently; or a mental state impeding compliance with the
program. Patients with other medical illnesses were included
provided they could manage the transport to the outpatients' clinic
on their own. No patient was excluded due to their medical disease.
The patients were asked not to change any nutritional supplements
or OA medication during the 16-week period of the study.
Treatment, randomization, and blinding
Subjects were randomly assigned to either 8 weeks of LED
(810 kcal/day) or a very-low-energy diet (VLED; 415 kcal/day) in
a supervised dietary program17. Following this all-provided
formula-diet period, all patients were instructed to follow an
additional 8-week period of a hypo-energetic diet consisting of
normal food plus meal replacements (anticipated approximately
1200 kcal/day in total). Both groups received identical nutritional
instructions and behavioral therapy provided by an experienced
dietician at weekly sessions (1.5 h/week) throughout the 16
weeks to reinforce and continuously stimulate the patients'
decision about weight reduction and to encourage a high degree
of compliance. During the 16-week intensive dietary treatment,
the amount of attention given to the groups was exactly the
same, in order to reduce the risk of performance bias. The LED
consisted of meal replacements, nutrition powder and bars (The
Cambridge Diet, the Cambridge Health and Weight plan UK),
which were taken three times a day. The nutrition powder was
dissolved in skimmed milk (7.5 dL of milk a day). The VLED
consisted of the same meal replacements as LED, but the nutri-
tion powder was dissolved in water, giving the patients only
415 kcal/day. Participants attended in groups of eight, and
although they knew they were receiving diets in the range
415e810 kcal/day, they were not overtly aware of the dietary
group to which they had been allocated. The LED used in this
study The Cambridge Health and Weight Plan is not on sale in
Denmark, so the patient had no foreknowledge of the products
and its energy content. The formula-diet sachets the participants
were provided with did not show the energy content. Both
dietary programs met all recommendations for daily intake of
vitamins and minerals. Daily intake of protein was at least 43.2 g,
essential fatty acids 3 g, and linolenic acid 0.4 g. Dietary ﬁber
intake was 7.2 g a day at least. Patients were advised to use
a ﬁber supplement to avoid constipation. The second phase of
the study was an 8 weeks (assumed) ﬁxed energy diet program
using 1200 kcal a day including two Cambridge products. All
patients were taught to make diet plans eating 5e6 small meals
a day. The principles of the diet were low-fat, low-sugar and
high-ﬁber. Patients were encouraged to eat at least 300 g of
vegetables a day and two portions of fruit. During this phase all
groups received the same nutritional education along with
recipes for low energy meals.
Blocks were enrolled for randomization based on 24 patients
consecutively included during the study period. Randomization
was done based on minimization18, according to (1) gender [M/F],
(2) BMI [30, 35, and 40, respectively] and (3) age-ensuring
homogeneity between intervention groups. In order to imple-
ment the allocation sequence, the groups were concealed until
interventions were assigned. Each randomization list was drawn up
by the statistician and given to the secretariat at The Parker Insti-
tute who subsequently informed the patients (who already had
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consent), when to meet with the dietitian (i.e., thus securing
a concealed allocation). This way the random assignment pre-
vented foreknowledge of forthcoming allocations by study partic-
ipants and those recruiting them to the trial19. The blinding was
maintained throughout the trial.
Assessment of efﬁcacy
The primary outcome of this study was the number of patients
responding to therapy according to the OMERACTeOARSI
responder criteria13,20. The criteria are deﬁned as high improve-
ment in pain or function (50%) and an absolute change 20%, or
an improvement in at least 2 of the 3 following: pain 20% and
absolute change 10%; function 20% and absolute change 10%;
patient's global assessment 20% and absolute change 10%14.
The three items of the OMERACTeOARSI responder criteria were
assessed using a 10 cm visual analogue scale (VAS) with separate
results for pain, disability and global evaluation of the patient.
The secondary outcome was the changes in symptoms of knee
OA, as perceived by patients prior to and after intervention (week
16), this was monitored by the following questionnaires: the Knee
injury and Osteoarthritis Outcome Score (KOOS)21,22, being
a normalized score, 100 indicating no symptoms and 0 indicating
extreme symptoms, and the Short-Form-36 (SF-36)23. In order to
assess the 8-week efﬁcacy the KOOS and the OMERACTeOARSI
related questionnaires were ﬁlled out by the patients at the 8 week
visit.
The following are exploratory outcomes. The changes in body
weight were examined as an independent predictor of changes in
the symptoms of knee OA. At baseline and after 8 and 16 weeks the
body weights of all patients were measured on a decimal weighing
scale (TANITA BW-800, ‘Frederiksberg Vægtfabrik’, Copenhagen,
Denmark). Height was measured using a stadiometer, rounding off
the values to the nearest 0.5 cm. Body composition was measured
with Dual-energy X-ray (DEXA-Lunar DPX IQ Full Body Bone
Densitometer) scanning at baseline and after 16 weeks of
intervention. Bi-plane weight-bearing semi-ﬂexed (15) radio-
graphs were taken of the target knee (in case of bilateral symptoms
we used the most symptomatic knee); one in the posteroanterior
view and one in the lateral-medial view. They were obtained at
baseline, using a Philips Optimus apparatus, and the same radiog-
raphers using a standardized protocol carried out all examinations
at the same department of radiology.
Assessment of safety
Reporting of adverse events was elicited with a non-leading
question at all clinic visits, including baseline. All events were
coded according to the Medical Dictionary for Regulatory Activities,
as currently required by all regulatory authorities including the US
Food and Drug Administration and the European Agency for the
Evaluation of Medicinal Products. Routine laboratory tests,
including measurement of serum glucose levels for estimating
effects on glucose homeostasis and administration of liver function
tests, were performed at baseline and together with each of the
subsequent outcome assessments (i.e., week 8 and 16).
Sample size and power considerations
Patients included in this study were destined to participate in
a subsequent 1-year maintenance program, ClinicalTrials.gov
Identiﬁer: NCT00655941. No speciﬁc sample size calculation was
performed.Statistical analysis
All data analyses were carried out according to a pre-
established analysis plan; all analyses were done applying SAS
software (v. 9.1.3 Service Pack 4; SAS Institute Inc., Cary, NC, USA).
All descriptive statistics and tests are reported in accordance to
the recommendations of the “Enhancing the QUAlity and Trans-
parency Of health Research” (EQUATOR) network: the CONSORT
statement24. In order to evaluate the empirical distributions of the
continuous outcomes, visual inspection was used to suggest
whether the assumption of normality was reasonable. The PROC
UNIVARIATE statement was used for summarizing the data. All
analyses were conducted according to the intention-to-treat (ITT)
principle; i.e., analyzing participant outcomes according to the
group to which they were randomized, even if some participants
did not receive dietary attention. This was done based on a basic
imputation technique, replacing missing data with the value at
baseline carried forward25. Two sided signiﬁcance tests were
used.
Proportions were compared by estimating the risk difference
with 95%CIs for each dichotomous outcome; including a Wald-
Z-test testing the hypothesis that there was no difference between
the proportions26. For sensitivity, if the Wald-test indicated statis-
tical signiﬁcance (P< 0.10) a c2-test with continuity correction or
Fisher's exact test were applied when appropriate. Changes in the
continuous outcome data, assumed sampled from a normal
distribution, were analyzed using two-sample t-test for means,
using the Satterthwaite approximation assuming unequal variances
by default. The PROC TTEST was used for these with corresponding
mean differences and 95%CIs. If the assumption of normality was
not reasonable, we analyzed the data with the nonparametric
Wilcoxon Rank Sum test using PROC NPAR1WAY; in this case the
mean difference was replaced with median differences using the
ROBUSTSCALE option based on the interquartile range applicable
for estimating robust 95% CIs.Results
Patient characteristics
The total number of persons prescreened via telephone during
the 9 months recruitment period was 388 (Fig. 1). Of these, 187
(48%) of 388 were ineligible, and 9 (2%) of 388 declined to
participate at the screening visit, leaving 192 patients randomized
and included (Table I). The typical knee OA patient participating in
this study was a 62-year old woman, with a BMI of 37, repre-
senting 25e30 kg of excess body weight. The KeL score and the
KOOS scores were as shown in Table I. Of the 192 patients 170
(89%) had bilaterally knee OA, with 21 (12%) having a TKA on the
contra laterally knee. Of the 192 patients being randomized, 175
(91%) completed the study (returned for the ﬁnal data collection
at week 16). The 17 study participants who did not complete the
study were not signiﬁcantly different from those who remained in
terms of age, sex, BMI, initial radiographic score, knee pain or
physical function. Retention of participants was not signiﬁcantly
different between the two groups (VLED and LED). In the ﬁrst 8
weeks 14 participants dropped out; 12 due to non-compliance
(VLED, 8; LED, 4) and 2 due to adverse events. In the second
8-week period, three participants dropped out due to non-
compliance (VLED, 2; LED, 1); none due to adverse events
(Fig. 1). In the VLED group, adherence was 91%, deﬁned as
attendance at the 8-week followup, and 90% after 16 weeks
(deﬁned as attendance at week 16). For those randomized to the
LED diet, adherence was 94% after 8 weeks and 93% after 16
Fig. 1. Progress of participants through CAROT-study. Abbreviations: ITT, Intention-to-treat population.
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between the two intervention groups.
Both groups (VLED and LED) lost on average 12% of their
initial body weight, with 57 (59.4%) of 96 loosing 10% of their
body weight in the LED group after 8 weeks and 66 (68.8%) of 96
in the VLED group (Table II, Fig. 2). After 16 weeks there were 71
(74.0%) of 96 having lost 10% of their body weight in both the
VLED group and in the LED group (Table II). The changes in body
weight corresponded to a highly signiﬁcant reduction in BMI of
4.8 kg/m2 in the VLED group and 4.0 kg/m2 in the LED group
(P< 0.001). Only part of the participants was above the World
Health Organization (WHO) deﬁnition of morbid obesity
(BMI 40). On the suggestion of the reviewer, we have addeda post-hoc analysis of the weight loss for this group of partici-
pants (n¼ 43), weight-loss average 12.4 kg (95%CI: 14.7 to
10.2), corresponding to 10.8%.
Primary outcome
At 16 weeks, proportions of the VLED and LED groups, 59
(61.5%), and 63 (65.6%) patients, respectively, met the OMER-
ACTeOARSI responder criteria (Table II), with no statistical signif-
icant difference between the groups; 4.2%point (95%CI: 18.0 to
9.0; P¼ 0.55). Combining the groups the pooled estimate was 64%
meeting the OMERACTeOARSI responder criteria (95%CI: 57e70%)
after 16 weeks. After the ﬁrst 8 weeks 55 (57%) of 96 in the LED
Table I
Baseline characteristics of the patients in the ITT population
Characteristic Treatment Combined
VLEDN¼ 96 LED N¼ 96 Total NTotal¼ 192
Female, no. (%) 78 (81.3%) 77 (80.2%) 155 (80.7%)
Age (years) 61.8 6.4 63.3 6.3 62.5 6.4 (50.0e77.9)
Duration (years)* 3.0 [1.0; 4.5] 3.0 [1.0; 4.0] 3.0 [1.0; 4.0] (1.0e29.0)
Height (m) 1.66 0.08 1.66 0.08 1.66 0.08 (1.48e1.91)
Weight (kg) 104.1 15.6 102.3 14.4 103.2 15.0 (76.0e145.3)
BMI (kg/m2) 37.5 5.4 37.1 4.1 37.3 4.8 (30.1e54.0)
Lean body mass (kg)y 50.8 8.2 50.8 9.1 50.8 8.7 (37.1e78.4)
Lean body mass (%)y 50.2 5.8 50.9 5.5 50.5 5.7 (38.0e67.7)
Fat mass (kg)y 48.1 10.5 46.2 8.3 47.1 9.5 (30.7e80.7)
Fat mass (%)y 47.1 6.1 46.3 5.7 46.7 5.9 (28.8e59.7)
Bone mineral content (%)y 2.8 0.4 2.8 0.3 2.8 0.4 (1.9e4.3)
Current smokers no. (%) 12 (12.5%) 7 (3.6%) 19 (9.9%)
Plasma glucose (mmol/L) 5.9 0.7 6.1 1.0 6.0 0.9 (4.8e11.1)
C-reactive protein (mg/L)* 4.1 [2.3; 8.1] 4.6 [2.4; 7.1] 4.4 [2.4; 7.7] (0.7e58.6)
Kellgren and Lawrence radiographic reading, no. (%)z
Grade 1 7 (7.4%) 10 (10.5%) 17 (9.0%)
Grade 2 38 (40.0%) 33 (34.7%) 71 (37.4%)
Grade 3 35 (36.8%) 33 (34.7%) 68 (35.8%)
Grade 4 15 (15.8%) 19 (20.0%) 34 (17.9%)
KOOS
Pain 57.2 17.2 57.4 15.1 57.3 16.1 (11.1e100)
Symptoms 60.2 16.7 61.2 17.6 60.7 17.1 (14.3e96.4)
ADL 59.0 16.9 60.8 17.9 59.9 17.4 (4.7e98.5)
Sports/recreation 19.6 18.1 25.6 21.1 22.6 19.9 (0e100)
QOL 36.9 16.5 39.5 16.5 38.2 16.5 (0e81.3)
OMERACTeOARSI items
Pain 43 20 42 20 43 20 (2e94)
Disability 45 21 42 22 43 22 (1e93)
Global 33 21 35 24 34 23 (0e93)
SF-36 score
Physical component 33.3 8.9 34.3 8.5 33.8 8.7 (11.7e60.9)
Mental component 52.6 11.9 54.2 11.5 53.4 11.7 (16.4e73.0)
Pluseminus values are means SD and (minimumemaximum) unless otherwise stated. The BMI is the weight in kilograms divided by the square of the height in meters. The
KOOS is a normalized score, 100 indicating no symptoms and 0 indicating extreme symptoms. The three items of the OMERACTeOARSI responder criterion can range from 0 to
100 on a VAS. Scores for the Medical Outcomes Study 36-items Short-Form General Health Survey (SF-36) can range from 4 to 71 for the physical component and from 2 to 74
for the mental component. For the OMERACTeOARSI and SF-36, higher scores indicate more severe disease.
Abbreviations: VLED, Very-low-energy diet; LED, low-energy diet; KOOS, Knee injury and Osteoarthritis Outcome Score; ADL, Function in daily living; QOL, Quality Of Life;
OMERACT, the Outcome Measures in Rheumatology; OARSI, The Osteoarthritis Research Society International; SF-36, short-form-36.
* Presented as median, interquartile range [Q1;Q3] and (minimumemaximum).
y Lean body mass, fat mass and bone mineral content was measured using Dual-Energy X-ray Absorptiometry.
z Only 91 evaluations in each group.
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ACTeOARSI responder criterion (Fig. 2).Secondary outcomes
KOOS
There was an overall improvement in all ﬁve subgroups in the
KOOS score for both the LED and the VLED groups, all of minimal
perceptible clinical improvement (8e10 points)27 (Table II). The
groups showed no difference in effect, with a pooled average for
pain 9.72 (95%: 7.72e11.72; P< 0.001), symptoms 9.04 (95%:
7.17e10.91; P< 0.001), Function in daily living (ADL) 11.07 (95%:
9.11e13.03; P< 0.001), sports/recreation 8.60 (95%: 5.79e11.40;
P< 0.001) and quality of life (QOL) 8.58 (95%: 6.33e10.83;
P< 0.001), respectively. The greatest improvement in both groups
was seen in the Activity of Daily Living subgroup of the KOOS.
SF-36
There was an overall improvement in both the physical and
mental component of the SF-36 in both the VLED and the LED
group. There was a statistically signiﬁcant greater improvement in
the mental component of the SF-36 in the VLED group compared to
the LED group (P¼ 0.01) (Table II).Safety
As presented in Table III the most statistically signiﬁcant
difference in adverse event reported in the VLED and LED group
was epigastric pain 12 (12.5%) and 4 (4.2%); P¼ 0.035.
Five serious adverse events occurred during the study. These
were mostly cardiovascular events as seen regularly in this age
group. However, one patient in the LED group experienced brady-
cardia, andwas brieﬂy hospitalized. This patient had lost more than
14 kg within 8 weeks, while not adjusted her dosage of metoprolol
medication.When her dosage of metoprolol had been adjusted, she
was discharged from hospital with no further events of brady-
cardia, and continued in the study.
One patient in the LED group developed an allergic reaction and
was excluded after the ﬁrst week, this was probably due to allergy
towards the formulated diet, and the patient was not hospitalized.Discussion
The present study showed a highly signiﬁcant improvement in
symptoms in obese patients with knee OA following a 16-week
intervention consisting of a LED program leading to a majority of
the participants losing more than 10% of their body weight. The
Table II






Difference in means (95%CI) P-value
Primary outcome
OMERACTeOARSI response at end
of followup, no. (%)
59 (61.5%) 63 (65.6%) 4.2 (18.0 to 9.0) 0.55
Pain 11.6 1.90 10.5 1.83 1.10 (4.11 to 6.32) 0.68
Disability 14.44 2.25 12.75 1.93 1.69 (4.16 to 7.54) 0.57
Global 9.64 2.12 11.54 2.09 1.90 (7.78 to 3.96) 0.52
Secondary outcomes
DWeight (kg) 13.3 0.65 12.22 0.59 1.08 (0.67 to 2.81) 0.22
DWeight (%) 12.94 0.59 11.96 0.55 0.98 (0.61 to 2.56)
D BMI (kg/m2) 4.79 0.23 4.02 0.21 0.34 (0.27 to 0.96) 0.27
Losing 10% body weight, no. (%) 71 (74.0%) 71 (74.0%) 0.0 (6.0 to 12) 1.0
KOOS
D Pain 8.88 1.47 10.56 1.42 1.68 (2.35 to 5.72) 0.41
D Symptoms 9.26 1.33 8.82 1.37 0.44 (4.21 to 3.33) 0.82
D ADL 11.01 1.50 11.13 1.33 0.12 (3.84 to 4.08) 0.95
D Sports/recreation 8.75 1.81 8.44 2.24 0.31 (6.0 to 5.37) 0.91
D QOL 8.31 1.64 8.85 1.60 0.54 (3.98 to 5.06) 0.81
SF-36
D Physical component 5.57 0.83 6.07 0.81 0.50 (1.79 to 2.78) 0.67
D Mental component 4.43 0.82 1.32 0.89 3.11 (5.49 to 0.73) 0.01
Change in outcomes from baseline after 16 weeks in knee OA patients who were randomized to either the VLED or LED.
Values are mean standard error (SE) unless otherwise stated.
Abbreviations: VLED, Very-low-energy diet; LED, low-energy diet; KOOS, Knee injury and Osteoarthritis Outcome Score; ADL, Function in daily living; QOL, Quality Of Life;
OMERACT, the Outcome Measures in Rheumatology; OARSI, The Osteoarthritis Research Society International; SF-36, short-form-36.
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fulﬁlling the OMERACTeOARSI responder criteria for symptom
improvement at 16 weeks. The results fulﬁlled the expectations of
an intensive dietary program in these patients9,11 and were similar
to the effect on OA symptoms by weight loss previously shown in
trials using LEDs, nutrition class or weight reducing drugs for 8e72
weeks10,28e33. Several circumstances may explain why we did not
ﬁnd a difference in the weight losses between the LED and VLED
groups. While dieting, individuals on both LEDs and VLEDs will
show a decrease in energy expenditure probably due to a loweringFig. 2. Clinical efﬁcacy following 16 weeks therapy. A: Proportion of patients loosing 10
therapy according to the OMERACTeOARSI responder criterion after 8 and 16 weeks. :¼
classiﬁed as a high improvement in pain or function (50%) and an absolute change
change 10%; function 20% and absolute change 10%; patient's global assessment 20%of the basic metabolic rate (BMR) and a lower physical activity level.
The reduced BMR is probably an adaptive mechanism to protect the
organism during starvation, and as such it also slows the weight
loss during dieting. One likely explanation as to why the VLED
group did not lose signiﬁcantly more weight than the LED group is
that the VLED group experienced a greater degree of fall in energy
expenditure than did the LED group. Another explanation could be
lower compliance in the VLED group comparedwith that in the LED
group. The VLED gives only 415 kcal and a lower supply of dietary
protein. This could result in more hunger and more occasions of% of their body weight after 8 and 16 weeks. B: Proportion of patients responding to
VLED, -¼ LED. A response according to the guidelines of the OMERACTeOARSI was
20%, or an improvement in at least 2 of the 3 following: pain 20% and absolute
and absolute change 10%.
Table III







Abdominal and intestinal symptoms
Nausea 7 (7.3%) 6 (6.3%) 1.0 (6.1 to 8.1)
Diarrhoea 4 (4.2%) 3 (3.1%) 1.0 (4.3 to 6.3)
Constipation 28 (29.2%) 25 (26.0%) 3.1 (9.5 to 15.8)
Wind/Flatulence 34 (35.4%) 29 (30.2%) 5.2 (8.1 to 18.5)
Epigastric pain 12 (12.5%) 4 (4.2%) 8.3 (0.6 to 16.1)*
Vomiting 4 (4.2%) 3 (3.1%) 1.0 (4.3 to 6.3)
Abdominal pain 8 (8.3%) 7 (7.3%) 1.0 (6.5 to 8.6)
Heartburn 6 (6.3%) 2 (2.1%) 4.2 (1.5 to 9.8)
Biliary symptoms 2 (2.1%) 4 (4.2%) 2.1 (7.0 to 2.8)
Musculoskeletal symptoms
Cramps 6 (6.3%) 5 (5.2%) 1.0 (5.5 to 7.6)
Joint paint 7 (7.3%) 11 (11.5%) 4.2 (12.4 to 4.1)
Back pain 11 (11.5%) 12 (12.5%) 1.0 (10.2 to 8.1)
Swollen joints 10 (10.4%) 7 (7.3%) 3.1 (4.9 to 11.1)
Sciatic pain 9 (9.4%) 6 (6.3%) 3.1 (4.5 to 10.7)
Central nervous system and psychiatric symptoms:
Dizziness 19 (29.8%) 12 (12.5%) 7.3 (3.1 to 17.6)
Headache 12 (12.5%) 6 (6.3%) 6.3 (1.9 to 14.4)
Anxiety 5 (5.2%) 4 (4.2%) 1.0 (4.9 to 7.0)
Sleeplessness 15 (15.6%) 10 (10.4%) 5.2 (4.3 to 14.7)
Fatigue 14 (14.6%) 12 (12.5%) 2.1 (7.6 to 11.8)
Mood changes 10 (10.4%) 4 (4.2%) 6.3 (1.1 to 13.6)*
Depressive tendencies 6 (6.3%) 3 (3.1%) 3.1 (2.8 to 9.1)
Skin and subcutaneous symptoms:
Dry skin 18 (18.8%) 12 (12.5%) 6.3 (4.0 to 16.5)
Allergic rash 11 (11.5%) 8 (8.3%) 3.1 (5.3 to 11.6)
Redness 3 (3.1%) 6 (6.3%) 3.1 (9.1 to 2.8)
Eczema 6 (6.3%) 7 (7.3%) 1.0 (8.1 to 6.1)
Perianal itching 3 (3.1%) 7 (7.3%) 4.2 (10.4 to 2.1)
Skin irritation 8 (8.3%) 5 (5.2%) 3.1 (4.0 to 10.2)
Urticaria 2 (2.1%) 2 (2.1%) 0.0 (4.0 to 4.0)
Miscellaneous symptoms:
Sensitive to cold 18 (18.8%) 14 (14.6%) 4.2 (6.4 to 14.7)
Inﬂuenza 4 (4.2%) 3 (3.1%) 1.0 (4.3 to 6.3)
Hair loss 7 (7.3%) 6 (6.3%) 1.0 (6.1 to 8.1)
Bad breath 17 (17.7%) 8 (8.3%) 9.4 (0.1 to 18.8)
Toothache 10 (10.4%) 9 (9.4%) 1.0 (7.4 to 9.5)
Data is presented as proportions no%; mean. Difference is estimated via the risk
difference.
Abbreviations: VLED, Very-low-energy diet; LED, low-energy diet.
*P< 0.05.
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less weight loss in this group. Compliance with LED and VLED
programs is difﬁcult; nevertheless, it is the cornerstone of
successful treatment.
Thus, this trial further supports the recommendation that
“patients with hip and knee OA, who are overweight, should be
encouraged to lose weight and maintain their weight at a lower
level”12. The proportion of OMERACTeOARSI responders according
to the KellgreneLawrence score of the worst compartment of the
knee was KL 1 (71%), 2 (62%), 3 (68%), 4 (59%), respectively (n.s.).
Patients with even severely affected knees (KeL grades> 3) can
lose weight using this program, and have a signiﬁcant relief in
symptoms to the same extent as the patients with KeL grades 0e2,
leading to the motto; “bad knees are no excuse for not losing
weight”.
This phase of our study focused on the dietary intervention and
it may be discussedwhether a concomitant exercise programmight
provide additional beneﬁts. In any case, the patients showed
improvement in both ADL and sports/recreation subgroup of the
KOOS scale with the greatest improvement in ADL of the ﬁve
subgroups, suggesting a more active lifestyle.
In the group of patients loosing more than 10% of their body
weight 75% were responders according to the OMERACTeOARSIresponder criteria, compared to only 30% in the group of patients
loosing less than 10% of their body weight (P< 0.0001) corre-
sponding to a Number Needed to Treat (NNT) of 3. The relief caused
by the weight loss was in the same range as that predicted by
a metaanalysis11 and substantiates the notion that a weight loss of
10% might be the best way of treating knee OA in obese patients.
Indeed, according to published metaanalyses of the overall efﬁcacy,
the weight loss may give the participants as effective or even better
symptomatic treatment than e.g., light exercises29 or NSAIDs34.
Indirect comparisons have not yet been published on the various
therapies in OA, but according to other studies the size of responses
on Non-steroidal anti-inﬂammatory drug (NSAID) vs placebo is
65.4% and 45.9%, respectively13.
In our study, we experienced a very good compliance with a low
drop-out rate; 91% of the participants remained in the study after
16 weeks, meaning that the program was well accepted by the
patients.
In general, the intensive diets gave few andmild adverse effects.
One serious adverse event presumably happened due to a too large
dose of metoprolol in a patient. The reduction of e.g., antihyper-
tensive and antidiabetic medications during intensive diets repre-
sents the only challenge for the treating physician35 and with this
reservation any individual irrespective of age, sex, weight or BMI
may be enrolled into a program of this typewhatever other medical
conditions may be present. All participants were asked not to
change their medication, and almost all claimed not to have done
this. However, in this pragmatic trial, we did not issue diaries for
control purposes and thus have no data on the actual consumption
over the 16 weeks. The end points were registered on days without
suchmedication, i.e., thepatientswere fasting fromthenight before.
This study showed an effect after 16weeks of intervention, but it
remains to be shown that patients will adhere to such program over
the coming years. By experience, most patients will regain their lost
weight when left on their own36, however, a maintenance of the
weight loss would be expected to be mandatory for continuous
relief37. There is still a challenge in getting the patients to maintain
their weight on a lower level. Exercise was shown to be beneﬁcial
for weight maintenance38. Thus, following an initial intensive
weight-loss program, an exercise intervention together with
a continuous weight management program would probably be the
best treatment for continuous weight management of the obese
with knee OA. There is a need for this type of maintenance studies
in knee OA patients. A possible effect of weight loss on structural
damage is yet to be shown, and the evidence for long term effects of
weight loss and weight maintenance on OA is sparse.
In conclusion, our dietary program resulted in a fast and effective
weight loss with very few adverse events resulting in a highly
signiﬁcant improvement in symptoms. Within this timeframe,
weight loss by dietary programs is at least as effective as, andmay be
advocated before considering surgical or pharmacological treat-
ments, which are associated with less advantageous safety
proﬁles39,40. The programused in this study could be administered to
patients of all ages; concurrentmedical diseases were not a barrier to
successful weight loss. In fact, such rapid weight loss only presents
one major challenge to the treating physician: to reduce medication
such as analgesics/NSAID's and for the components of the metabolic
syndrome, especially antihypertensive and antidiabetic medications,
which may in some cases be withdrawn altogether.
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